

# The *Caenorhabditis elegans* mRNA 5'-Capping Enzyme

IN VITRO AND IN VIVO CHARACTERIZATION\*

Received for publication, November 27, 2002, and in revised form, January 31, 2003  
Published, JBC Papers in Press, February 7, 2003, DOI 10.1074/jbc.M212101200

Toshimitsu Takagi<sup>‡§</sup>, Amy K. Walker<sup>¶</sup>, Chika Sawa<sup>‡||</sup>, Felix Diehn<sup>‡\*\*</sup>, Yasutaka Takase<sup>‡ ‡‡</sup>,  
T. Keith Blackwell<sup>¶</sup>, and Stephen Buratowski<sup>‡§§</sup>

From the <sup>‡</sup>Department of Biological Chemistry and Molecular Pharmacology and <sup>¶</sup>Center for Blood Research and  
Department of Pathology, Harvard Medical School, Boston, Massachusetts 02115

Eukaryotic mRNA capping enzymes are bifunctional, carrying both RNA triphosphatase (RTPase) and guanylyltransferase (GTase) activities. The *Caenorhabditis elegans* CEL-1 capping enzyme consists of an N-terminal region with RTPase activity and a C-terminal region that resembles known GTases. However, CEL-1 has not previously been shown to have GTase activity. Cloning of the *cel-1* cDNA shows that the full-length protein has 623 amino acids, including an additional 38 residues at the C termini and 12 residues at the N termini not originally predicted from the genomic sequence. Full-length CEL-1 has RTPase and GTase activities, and the cDNA can functionally replace the capping enzyme genes in *Saccharomyces cerevisiae*. The CEL-1 RTPase domain is related by sequence to protein-tyrosine phosphatases; therefore, mutagenesis of residues predicted to be important for RTPase activity was carried out. CEL-1 uses a mechanism similar to protein-tyrosine phosphatases, except that there was not an absolute requirement for a conserved acidic residue that acts as a proton donor. CEL-1 shows a strong preference for RNA substrates of at least three nucleotides in length. RNA-mediated interference in *C. elegans* embryos shows that lack of CEL-1 causes development to arrest with a phenotype similar to that seen when RNA polymerase II elongation activity is disrupted. Therefore, capping is essential for gene expression in metazoans.

Most eukaryotic and viral mRNAs are modified at their 5' end by a "cap" structure that consists of a 7-methylguanosine moiety attached to the 5' terminus via a 5'-5' linkage (1). Three sequential enzymatic activities are required to form the "cap 0" structure, m<sup>7</sup>GpppN. First, an RNA 5'-triphosphatase (RTPase)<sup>1</sup> removes the  $\gamma$ -phosphate from the 5' end of the RNA

substrate to leave a diphosphate end. Next, a GTP::mRNA guanylyltransferase (GTase) catalyzes transfer of GMP from GTP, resulting in a 5'-5' linkage, GpppNp. These two activities are typically associated and copurify as mRNA capping enzyme. A third protein, RNA (guanine-7-)-methyltransferase, adds a methyl group to the N-7 position of the guanine cap (1, 2).

Previously we characterized a putative capping enzyme gene, which we named *cel-1*, that emerged from the *Caenorhabditis elegans* genome sequencing project (3). The open reading frame (ORF) of this gene originally predicted by the NematoSequencing Project was 573 amino acids. The C-terminal 340 amino acids exhibit very strong similarity to yeast and viral GTases. The N-terminal region has significant sequence similarity to the protein-tyrosine phosphatase (PTP) family, including the active site consensus motif (I/V)HCXXGXXR(S/T)G (4–7). We proved that the isolated N-terminal region (residues 1–236) of CEL-1 has RTPase activity (3, 8). However, we were unable to demonstrate that the C-terminal region had GTase activity.

The ORF used in the earlier study was based on predictions of exons within genomic sequence. Since then the *C. elegans* Expressed Sequence Tag (EST) data base has produced several cDNA sequences predicted to encode a longer form of CEL-1 that has additional residues at both the N and C termini. Protein produced from the longer ORF fully substitutes for the *Saccharomyces cerevisiae* GTase and RTPase *in vivo*. The longer CEL-1 C-terminal domain has GTase activity *in vitro*. We further characterized the isolated RTPase domain both *in vivo* and *in vitro*. We analyzed its catalytic properties, including the effect of RNA chain length on the activity. Mutagenesis confirms a mechanistically conserved role for key residues found in both the RTPase and PTPs. Surprisingly, the CEL-1 RTPase did not require linkage to the GTase for targeting to pre-mRNA in *S. cerevisiae*. Finally, we used RNA-mediated interference (RNAi) to demonstrate that CEL-1 is essential *in vivo* for development of *C. elegans*.

## EXPERIMENTAL PROCEDURES

**DNA Cloning Methods**—Supplementary tables listing oligonucleotides and plasmids used in this study are available at the Buratowski laboratory web site.<sup>2</sup> PCR for construction of plasmids and site-directed

\* This work was supported by National Institutes of Health Grants GM56663 (to S. B.) and GM62891 (to T. K. B.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§ Senior Postdoctoral Fellow of the American Cancer Society, Massachusetts Division. Present address: Dept. of Automated Biotechnology, Merck Research Laboratories, North Wales, PA 19454.

|| Postdoctoral Fellow For Research Abroad of the Japan Society for the Promotion of Science.

\*\* Present address: Mayo Clinic, Rochester, MN 55901.

‡‡ Present address: Laboratory of Seeds Finding Technology, Eisai Co., Ltd., Ibaraki 300-2635, Japan.

§§ A scholar of the Leukemia And Lymphoma Society. To whom correspondence should be addressed: Dept. of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, 240 Longwood Ave., Boston, MA 02115. Tel.: 617-432-0696; Fax: 617-738-0516; E-mail: steveb@hms.harvard.edu.

<sup>1</sup> The abbreviations used are: RTPase, RNA 5'-triphosphatase;

GTase, GTP::mRNA guanylyltransferase; PTP, protein-tyrosine phosphatase; RNAi, RNA interference; 5-FOA, 5-fluoroorotic acid; pol II, RNA polymerase II; CTD, C-terminal domain of the largest subunit of RNA polymerase II; CTD-P, phosphorylated CTD; HA, influenza virus hemagglutinin; EST, Expressed Sequence Tag; ORF, open reading frame; P-TEFb, positive transcription elongation factor b; CDK, cyclin-dependent kinase; kb, kilobase; DTT, dithiothreitol; ds, double-stranded; MCE, mouse capping enzyme; BVP, baculoviral PTP.

<sup>2</sup> T. Takagi, A. K. Walker, C. Sawa, F. Diehn, Y. Takase, T. K. Blackwell, and S. Buratowski, unpublished information.

mutagenesis were carried out with Vent DNA polymerase (New England BioLabs).

**Cloning of CEL-1 cDNA**—To obtain a full-length cDNA for CEL-1, a two-step Mega-Primer PCR was performed with two EST clones, yk786d02 and yk798b08 (supplied by Dr. Y. Kohara, National Institute of Genetics, Mishima, Japan). In the first reaction, a 1.2-kb fragment was amplified from the 5' region of *CEL-1* using CEL-1upstreamA and Cel1-4 as primers and yk786d02 as template. The product was purified and used in the second PCR as a megaprimer. The second reaction used yk798b08 as template and used 3'CEL-1longer and CEL-1upstreamA as primers for secondary amplification. A 1.8-kb product was subcloned into pCR-Script SK(+) (Stratagene) to produce pBS-CEL-1. To create CEL-1-(1-585), 3'CEL-1longer was replaced with Celeg. CE-C.

**Genetic Manipulation of *S. cerevisiae***—*S. cerevisiae* strains used in this study were YSB244 (*MATa ura3-52 leu2-3,112 his3Δ200 ceg1Δ1::HIS3* [pRS316-CEG1]) (9), YSB533 (*MATa ura3-52 leu2Δ1 trp1Δ63 his3Δ200 lys2Δ202 cet1Δ1::TRP1* [pRS316-CET1]) (10), and YSB719 (*MATa ura3-52 leu2Δ1 trp1Δ63 his3Δ200 lys2Δ202 cet1Δ1::TRP1 ceg1Δ3::LYS2* [pRS316-CEG1-CET1]) (11). We introduced plasmids into these strains using a modified lithium acetate transformation protocol (12). Media preparation, plasmid shuffling with 5-fluoroorotic acid (5-FOA), and other yeast manipulations were carried out by standard methods (13, 14).


**Yeast Whole-cell Extract Preparation and Protein Analysis**—Whole-cell extracts from *S. cerevisiae*, immunoprecipitation, and subsequent enzyme-GMP formation assay were as previously described (11).

**Site-directed Mutagenesis**—Site-directed mutagenesis was carried out using either single-stranded phagemid (15, 16) or PCR (17). In both strategies, the plasmid pBS-CEL-1-(13-585) (Ref. 3, listed as pBS-CEL-1 therein) was used as the template. Mutations were verified by dideoxy-DNA sequencing.

To change Arg-142 to Lys (R142K) or Ala (R142A), Asp-76 to Asn (D76N), and Glu-111 to Gln (E111Q), phagemid mutagenesis was performed with mutagenic oligonucleotides CEL1-R142K, CEL1-R142A, CEL1-D76N, or CEL1-E111Q. The resulting plasmids, pBS-CEL-1 R142K, pBS-CEL-1 R142A, pBS-CEL-1 D76N, and pBS-CEL-1 E111Q, served as template for subsequent PCR. Except for D76N, we amplified 0.7-kb fragments corresponding to RTPase domain containing those mutations using Celeg. CE-B and CEL-1T222stop as primers. For the wild type and the active site cysteine mutants, we used pBS-CEL-1-(13-585), pET-his7CEL-1-(13-248)C136S, and pET-his7CEL-1-(13-248)C136A as templates for the same PCR. Each product was subcloned into pCR-Script SK(+) to generate pBS-CEL-1-(13-221) version 2, pBS-CEL-1-(13-221)C136S version 2, pBS-CEL-1-(13-221)C136A version 2, pBS-CEL-1-(13-221)R142K version 2, pBS-CEL-1-(13-221)R142A version 2, and pBS-CEL-1-(13-221)E111Q version 2, respectively. We further subcloned inserts from these plasmids into yeast expression vector pAD5 (11) and bacterial expression vector pSBET-His<sub>7</sub> (18). For D76N, a 0.7-kb fragment was amplified with pBS-CEL-D76N as template and Celeg. CE-B and CEL1(3'Sac) as primers. The product was digested with *Nco*I and *Sac*I and subcloned into pAD5.

PCR-mediated site-directed mutagenesis was used to change Asp-112 to Asn (D112N). In the first reaction, a 0.3-kb fragment was amplified with CEL-1D112N and CEL-1T222stop. In the second reaction, primers were Celeg. CE-B and the product from the first reaction as a megaprimer. The product was subcloned onto pCR-Script SK(+) to produce pBS-CEL-1-(13-221)D112N.

**Recombinant Protein Production and Purification**—Mouse capping enzyme (MCE) full-length protein and the RTPase domains of MCE and CEL-1 were expressed using a T7 promoter/polymerase system (19). *Escherichia coli* strain BL21(DE3) was transformed with the appropriate expression plasmids and cultured in 500-ml media at 37 °C to an  $A_{600} = 0.5$ . The proteins were induced as described (18). All further operations were at 0–4 °C. Lysate was prepared by sonication in buffer B (50 mM Tris-HCl, pH 7.9, 10% (v/v) glycerol, 1 mM phenylmethylsulfonyl fluoride) with 300 mM KCl and 0.5% Nonidet P-40. After incubating soluble extracts (100,000 × g supernatant fraction) with 2 ml of nickel nitrilotriacetic acid-agarose resin (Qiagen) for 2 h on a rotator, the resin was poured into a column (1.5 × 2.5 cm) and extensively washed with buffer B with 20 mM KCl and 25 mM imidazole. Bound proteins were eluted with buffer B containing 20 mM KCl and 600 mM imidazole and immediately supplemented with 1 mM EDTA and 1 mM DTT. Proteins were further purified by chromatography with a column (1.2 × 9.0 cm) of heparin-Sepharose CL-6B (Amersham Biosciences). After washing the resin with 20 mM KCl in buffer C (20 mM Tris-HCl, pH 7.9, 1 mM EDTA, 1 mM DTT, 10% (v/v) glycerol, 1 mM phenylmethylsulfonyl fluoride), proteins were eluted with a 100-ml linear gradient of 20–300 mM KCl in buffer B. Purified proteins were visualized by



**FIG. 1. Detection of the capping enzyme-GMP covalent intermediate in *C. elegans* nuclear extract.** 3  $\mu$ M [ $\gamma$ - $^{32}$ P]GTP was incubated at 30 °C for 10 min with 20  $\mu$ g of *C. elegans* nuclear extract protein in 20 mM Tris-Cl, pH 7.5, 2 mM MnCl<sub>2</sub>, 5 mM DTT (lanes 2–7). Lane 1 is a control without protein. MnCl<sub>2</sub> was omitted in lanes 3 and 4, and an additional 2 mM EDTA was added in lane 4. Lane 5 is the same as lane 2 except 30  $\mu$ M unlabeled ATP was added. In lane 6, 30  $\mu$ M unlabeled GTP was added. In lane 7, the reaction mixture was incubated on ice instead of 30 °C for 10 min. After the reaction, proteins were separated by SDS-PAGE, and proteins covalently bound to GMP were visualized by autoradiography.

SDS-PAGE and Coomassie Brilliant Blue staining and by immunoblot analysis with monoclonal anti-polyhistidine antibody (anti-His<sub>6</sub>, Clontech).


**Preparation of Substrate for RTPase Assay**—[ $\gamma$ - $^{32}$ P]ATP- and [ $\gamma$ - $^{32}$ P]ATP-terminated oligoribonucleotides for the RTPase assay were synthesized with the DNA primase protein of bacteriophage T7 (8, 20). The standard reaction (100  $\mu$ l) contained 40 mM Tris-HCl, pH 7.5, 10 mM MgCl<sub>2</sub>, 10 mM DTT, 50  $\mu$ g/ml bovine serum albumin, 50 mM potassium glutamate, 2 mM dTTP, 2 mM CTP, 0.3 mM [ $\gamma$ - $^{32}$ P]ATP or [ $\alpha$ - $^{32}$ P]ATP (500–1000 cpm/pmol) (PerkinElmer Life Sciences), 1 nM synthetic oligonucleotide template, and 1  $\mu$ M (hexamer) T7 primase (21). The sequences of the oligonucleotides used are: diribonucleotide pppApC, 5'-(C)<sub>6</sub>GTC(T)<sub>25</sub>-3'; trinucleotide pppApCpC, 5'-(C)<sub>5</sub>GGTC(T)<sub>25</sub>-3'; tetranucleotide pppApCpCpC, 5'-(C)<sub>4</sub>GGGTC(T)<sub>25</sub>-3'; pentaribonucleotide pppApCpCpCpC, 5'-(C)<sub>3</sub>GGGGTC(T)<sub>25</sub>-3'. The reaction was incubated at 37 °C overnight. After extraction with phenol-chloroform (1:1), RNAs were precipitated with ethanol and dissolved in 500  $\mu$ l of buffer A (20 mM Tris-HCl, pH 7.9, 7 M urea) containing 100 mM NaCl. RNAs were further purified by chromatography with a column (1.0 × 27.0 cm) of DEAE-Sephadex A-25 (Amersham Biosciences) pre-equilibrated with buffer A with 100 mM NaCl. The column was washed with 300 ml of buffer A with 120 mM NaCl, and RNAs were eluted with a 700-ml linear gradient of 150–350 mM NaCl in buffer A. RNAs were analyzed with electrophoresis on a 36% polyacrylamide, 3 M urea gel and autoradiography. Samples were then pooled and dialyzed against 10 mM Tris-HCl, pH 8.0, 1 mM EDTA with Spectra/Por 7 (Spectrum). The RNAs were then lyophilized and dissolved in water. Previously, we used triethylamine bicarbonate (TEA-HCO<sub>3</sub><sup>-</sup>) buffer for the DEAE-Sephadex A-25 column chromatography (8). However, we observed that residual amounts of TEA-HCO<sub>3</sub><sup>-</sup>, contaminating the purified substrate, inhibit RTPase activity, and therefore, the protocol was modified as indicated. [ $\gamma$ - $^{32}$ P]GTP-terminated RNA was synthesized by *in vitro* transcription of linearized plasmid template (3) using recombinant polyhistidine-tagged T7 RNA polymerase (22).

**Enzymatic Assays**—GTPase, RTPase, and nucleotide phosphohydrolase activities were assayed as previously described (3, 8, 18).

**RNAi Analysis**—*In vitro* synthesized double-stranded (ds)RNA (Megascript, Ambion) was produced using pBS-CEL-1-(13-221) and pBS-CEL-1-(1-558) and injected at 1.0  $\mu$ g/ $\mu$ l into young adults (2–8 fertilized embryos). Equivalent results were obtained with *cel-1* RNAs covering the RTPase or GTase domains. *ama-1(RNAi)* and *cel-1(RNAi)* embryos were analyzed at 24 and 36 h post-injection, respectively, when uniform populations of arrested embryos appeared. For immunostaining, embryos were collected from dissected hermaphrodites 36 h after injection. Because most analyses were performed before terminal embryonic developmental arrest, RNAi effectiveness was confirmed by monitoring sibling embryos that were allowed to develop.

**Immunostaining**—For  $\alpha$ -CDK-9 (23, 24) and  $\alpha$ -pol II (25) staining, embryos were subjected to 2% paraformaldehyde fixation and freeze-cracked before treating with methanol. Washes and antibody incubations were performed in PBT (1× phosphate-buffered saline, 1% Triton X-100, 1% bovine serum albumin) before staining. Staining with the phosphorylated C-terminal domain (CTD-P) ( $\alpha$ -Ser(P)-5) (26) and H5 ( $\alpha$ -Ser(P)-2) (Berkeley Antibody Co.) was performed as in Walker *et al.* (27). Images were captured with a Zeiss AxioSKOP2 microscope and AxioCam digital camera, and antibody staining intensities were compared over a range of exposure times. Pixel intensities were standardized using Adobe Photoshop 6.0.





**Identification of an Extended *C. elegans* Capping Enzyme Open Reading Frame**—Previously, we (3) and others (28) found that the predicted gene C03D6 (GenBank™ accession number Z75525) from the *C. elegans* genome sequencing project had significant similarity to the yeast GTase. Similar capping enzyme genes from other metazoans were described (29–33). All of these proteins contain motifs found in the GTase proteins/domains of yeast and viruses (2, 28, 34–36; Fig. 2A) as well as an N-terminal domain related to the PTPs.

The protein encoded by the ORF for CEL-1 is somewhat shorter at the C terminus than its homologues from other species (Fig. 2A). Using the predictions of exon structure, we amplified a CEL-1 ORF from *C. elegans* cDNA. Although we could demonstrate RTPase activity of the N-terminal domain, we were not able to show GTase activity of the C-terminal domain. Therefore, we searched the EST data base ([www.ncbi.nlm.nih.gov/BLAST/](http://www.ncbi.nlm.nih.gov/BLAST/)) for naturally occurring CEL-1 cDNAs and found SP9F10 (accession number BE228078). This cDNA encodes an ORF containing the previously predicted amino acids 534–573 of CEL-1 but which has an extra 38 residues at the C terminus due to a splicing event that was not predicted from the genomic sequence. The *C. elegans* EST data base server at the DNA Data Bank of Japan ([www.ddbj.nig.ac.jp/c-elegans/html/CE\\_BLAST.html](http://www.ddbj.nig.ac.jp/c-elegans/html/CE_BLAST.html)) contains clone yk786d02 containing sequences for the 5' region of CEL-1. This encodes the previously identified RTPase domain (Refs. 3 and 8; designated residues 1–236 in those papers). However, there is an in-frame initiation codon 36-base upstream of the one previously believed to be the translation start site (Ref. 3; Fig.

2B). Combining this new cDNA information, full-length CEL-1 is predicted to have an additional 12 residues at the N terminus and 38 residues at the C terminus, for a total of 623 amino acids. The predicted molecular mass is 72 kDa, in good agreement with the size of the GTase detected in worm extract (Fig. 1). We therefore have renumbered the CEL-1 amino acids, and the previously analyzed shorter protein (3, 8) will herein be referred to as CEL-1-(13–585).


**CEL-1 Is a Bifunctional Capping Enzyme with Both RTPase and GTase Activities**—Unlike the metazoan enzyme, capping enzyme in the yeast *S. cerevisiae* is a complex of RTPase and GTase subunits (37). These polypeptides are encoded by the *CET1* and *CEG1* genes, respectively, both of which are essential for cell viability (38, 39). Ceg1 is related by sequence to the viral and metazoan GTases (2, 36). In contrast, Cet1 is not related to PTPs or metazoan RTPase domains (40).

We tested whether CEL-1 can function in place of *CEG1* and *CET1* in *S. cerevisiae* (Fig. 3A). The *ceg1Δcet1Δ* strain YSB719 (11) was transformed with a high copy plasmid expressing HA epitope-tagged CEL-1 from the constitutive *ADH1* promoter. An expression construct for the MCE was used as a positive control. After shuffling out the *CEG1/CET1* plasmid with 5-FOA, growth was observed with cells expressing either MCE or CEL-1. In contrast, expression of CEL-1-(1–585) did not rescue cells. Therefore, CEL-1 with the extended C terminus, but not the shorter form previously analyzed, has both capping enzyme RTPase and GTase activities.

A truncation mutant of MCE containing only the GTase domain (residues 211–597) can replace *CEG1* in *S. cerevisiae* (41). The corresponding domain of CEL-1 (residues 221–623, see Fig. 2A) supports viability (Fig. 3B) of the *ceg1Δ* strain YSB244 (9). Whole-cell extracts from yeast expressing CEL-1 were assayed for capping enzyme-GMP complex (Fig. 3C). A protein of about 70 kDa was detected (left panel, lane 2), the same size as that of the complex detected in *C. elegans* nuclear extract (Fig. 1). We also assayed extracts from yeast expressing either epitope-tagged CEL-1-(222–623) or CEL-1-(222–585) for the presence of protein by immunoblot using anti-HA monoclonal antibody 12CA5 (42) and for enzyme-GMP complex formation. Both proteins were detected in the immunoblot (data not shown). In contrast, GTase activity was detectable with CEL-1-(222–623) but not CEL-1-(222–585) (Fig. 3C, right panel, lane 3 and data not shown). These results again show that the residues 586–623 are important for CEL-1 GTase activity.

**The CEL-1 RTPase Domain Can Function Independently of the GTase Domain in Vivo**—We previously showed that CEL-1-(13–248) has RTPase activity *in vitro* (3, 8). Although full-length CEL-1 can simultaneously replace yeast Ceg1 and Cet1, we tested whether overexpression of CEL-1 derivatives could rescue *cet1Δ* strain YSB533 (10). Neither CEL-1 derivatives 1–221, 13–221, nor 1–585 could replace *CET1* (Fig. 4B and data not shown). However, this was not surprising because GTase activity was being supplied by Ceg1. The GTase associates with the phosphorylated C-terminal domain of the largest subunit of pol II (CTD-P) (29, 30, 41, 43). Ceg1 by itself is inactive on CTD-P unless it is interacting with the central region (amino acids 235–265) of Cet1 (10, 11). In contrast, the GTase domain of MCE (MCE-(211–597)) is activated by binding to CTD-P (44). The GTases from other fungi, *Schizosaccharomyces pombe* (pce1), and *Candida albicans* (Cgt1) do not require RTPase activation (45, 46).

To avoid the complications of Ceg1 dependence upon Cet1 interaction, the CEL-1 derivatives were assayed in cells expressing GTases from other organisms. In *ceg1Δcet1Δ* cells expressing pce1, Cgt1, or MCE-(211–597), the CEL-1 frag-




**FIG. 3. The CEL-1 GTase domain can replace Ceg1 in *S. cerevisiae*.** A, complementation of a double deletion mutant (*ceg1Δcet1Δ*) lacking both the GTase and RTPase. The *CEG1/CET1* shuffling strain YSB719 (11) was transformed with the following *LEU2*/2- $\mu$ m plasmids: vector (pAD5); MCE (pGL-MCE, expressing mouse capping enzyme MCE1 from the *GPD* promoter); CEL-1 (pAD5-CEL1, expressing CEL-1 from the *ADH1* promoter); CEL-1-(1–585) (pAD5-CEL-1-(1–585), expressing residues 1–585 of CEL-1 from the *ADH1* promoter). *Leu*<sup>+</sup> transformants were tested for growth after shuffling out pRS316-*CEG1-CET1* (11). B, complementation of *ceg1Δ* by the C-terminal region of CEL-1. The *CEG1* shuffling strain YSB244 (9) was transformed with following *LEU2*/2  $\mu$ m plasmids: vector (pAD5); *CEG1* (pAD5-*CEG1*); MCE-(211–597) (pAD5-MCE-(211–597) (11)); and CEL-1-(221–623) (pAD5-CEL-1-(222–623), expressing CEL-1-(222–623) from the *ADH1* promoter). *Leu*<sup>+</sup> transformants were tested for growth after plasmid shuffling (9). C, formation of a CEL-1-GMP intermediate. 10  $\mu$ g of yeast whole cell extract protein was incubated for 10 min at 30 °C with 3  $\mu$ M [ $\alpha$ -<sup>32</sup>P]GTP. After the reaction, the proteins were separated by SDS-PAGE and analyzed by autoradiography. Extracts were prepared from YSB719 transformed with pAD5 (left panel, lane 1) or pAD5-CEL-1 (left panel, lane 2) and YSB244 transformed with pAD5 (right panel, lane 1), pAD5-*CEG1* (right panel, lane 2) or pAD5-CEL-1 (222–628) (right panel, lane 3). Note that at this exposure the endogenous Ceg1 is not visible.

ments 1–221, 13–221, or 1–585 could support viability (Fig. 4 and data not shown). When overexpressed in *ceg1Δcet1Δ* strain in combination with MCE-(211–597), cells containing Cet1 formed colonies after 1 day, whereas cells containing either CEL-1-(13–221) or MCE-(1–210) formed colonies after 3 days (Fig. 4A). Both *S. pombe* pce1 and *C. albicans* Cgt1 GTases could also combine with the CEL-1 or MCE RTPase domains to support viability, but the *Chlorella* virus GTase A103R (34) could not (Fig. 4B). A103R could not complement a *ceg1Δ* strain either even though enzyme-GMP complex was detectable in lysates.<sup>3</sup>

To determine whether the mouse and *C. elegans* RTPase domains were interacting with the GTases or, instead, were independently acting at mRNA 5' ends, immunoprecipitation

<sup>3</sup> T. Takagi, unpublished observation.







**FIG. 4. The isolated metazoan RTPase domain can replace Cet1 in *S. cerevisiae*.** **A**, complementation by plasmid shuffling. YSB719 was transformed with pDB20H-MCE-(211-597). A His<sup>+</sup> isolate was subsequently transformed with the following *LEU2/2-μm* plasmids: vector (pRS425 (81)); *CET1* (pAD5-CET1); *CEL-1* (13-221) (pAD5-CEL-1(13-221), expressing CEL-1(13-221) tagged with an HA epitope from the *ADH1* promoter); *MCE* (1-210) (pAD5-MCE-(1-210), expressing MCE(1-210) tagged with the HA epitope from the *ADH1* promoter). Leu<sup>+</sup> His<sup>+</sup> transformants were tested for growth in the presence of 5-FOA to shuffle out pRS316-CEG1-CET1. **B**, YSB719 was transformed with pAD5-CEL-1(13-221) (left plate) or pAD5-MCE-(1-210) (right plate). Leu<sup>+</sup> isolates were subsequently transformed with the following *HIS3/2-μm* plasmids: vector (pRS423 (81)), *CEG1* (pRSH-CEG1), *MCE*-(211-597) (pDB20H-MCE-(211-597)), *CGT1* (pRSH-CGT1), *pce1*<sup>+</sup> (pDB20H-pce1<sup>+</sup>), or A103R (pDB20H-A103R, expressing the *Chlorella* virus GTase A103R from the *ADH1* promoter). Growth was tested after plasmid shuffling. **C**, immunoprecipitation and GTase-GMP intermediate formation assay. YSB719 transformants selected by 5-FOA were grown in selective media, and whole-cell extracts were prepared. Lane 1 has extract from YSB719 transformed with pAD5 and pDB20H-pce1<sup>+</sup>. This extract was prepared from cells without being selected by 5-FOA. Lanes 2 and 3 have extracts from the same strain transformed with pAD5-CET1 and either pRSH-CGT1 (lane 2) or pDB20H-pce1<sup>+</sup> (lane 3), respectively. Lane 4 is from cells containing pAD5-CEL-1(13-221) and pDB20H-pce1<sup>+</sup>. Lane 5 is from cells containing pAD5-CEL-1(13-221) and pRSH-CGT1. Lane 6 is from cells containing pAD5-MCE-(1-210) and pDB20H-pce1<sup>+</sup>. Lane 7 is from cells containing pAD5-MCE-(1-210) and pRSH-CGT1. Immunoprecipitation was carried out with 10 μg of extract protein, protein A-Sepharose beads, and monoclonal antibody 12CA5. Precipitates were incubated for 15 min at 30 °C with 3 μM [ $\alpha$ -<sup>32</sup>P]GTP and processed to SDS-PAGE. Proteins were transferred to nitrocellulose membrane and analyzed by immunoblotting with 12CA5 (upper panel) and autoradiography to detect radiolabeled GTase-GMP covalent intermediate (middle panel). The lower panel shows the result of GTase-GMP formation with 20 μg of whole-cell extract protein. The asterisks denote the position of radioactive phosphate. The only combination that shows an interaction is *S. cerevisiae* Cet1 and the *C. albicans* Cgt1 (lane 2).

experiments were carried out. Epitope-tagged Cet1, CEL-1(13-221), or MCE(1-210) were co-expressed with either pce1 or Cgt1. The RTPases were immunoprecipitated with 12CA5 (Fig. 4C). The top panel shows that each of the RTPases was expressed and immunoprecipitated efficiently. The precipitate was assayed for guanylation with [ $\alpha$ -<sup>32</sup>P]GTP to detect any GTase (Fig. 4C, middle panel). Lane 2 shows HA-Cet1 coprecipitates the *C. albicans* GTase Cgt1. In contrast, lane 3 shows that HA-Cet1 does not interact with the *S. pombe* GTase pce1. These findings confirm our earlier observation that pce1 functions without any interaction with RTPase protein (46). Under the same conditions, neither pce1 (lanes 4 and 6) nor Cgt1 (lanes 5 and 7) is coprecipitated with the RTPases CEL-1(13-221) or MCE(1-210). Therefore, we conclude that the overexpressed metazoan RTPase domains can function *in vivo* without linkage to the GTase domain.

Presumably, CEL-1(13-221) and MCE(1-210) do not support growth of a *cet1Δ* strain because they do not bind and activate Ceg1. To confirm this, regions of Cet1 were fused to the RTPase domain of CEL-1(13-221). The chimeras were co-expressed along with Ceg1 overexpressed from a 2-μm plasmid in a *cet1Δceg1Δ* strain (Fig. 5). Cet1(1-225)-CEL-1(13-221) cannot functionally replace Cet1. In contrast, Cet1(1-265)-CEL-1(13-221), which contains the Ceg1 interaction region (amino acids 235-265), can support viability. When amino acids 1-265 are derived from the mutant *cet1*-446 (P245A/W247A), which is disrupted for the ability to interact with Ceg1 (11), the ability to replace Cet1 was disrupted. All



**FIG. 5. The addition of the Ceg1-interacting region from Cet1 onto CEL-1 RTPase domain allows it to function in the presence of Ceg1.** YSB719 was transformed with (left) pRSH-CEG1 or (right) pDB20H-MCE-(211-597). His<sup>+</sup> isolates were subsequently transformed with the following *LEU2/2 μm* plasmids: vector (pAD5); *CET1* (pAD5-CET1); *CET1*-(1-225)-*CEL-1*-(13-221) (pAD5-CET1 (1-225)-CEL-1(13-221), expressing a fusion protein containing residues 1-225 of Cet1 and CEL-1(13-221) tagged with the HA epitope); *CET1*-(1-265)-*CEL-1*-(13-221) (pAD5-CET1 (1-265)-CEL-1(13-221)); *cet1*-446-(1-265)-*CEL-1*-(13-221) (pAD5-cet1-446-(1-265)-CEL-1(13-221), expressing a fusion protein consisting of residues 1-265 from the *cet1*-446 mutant (11) and CEL-1(13-221) tagged with the HA epitope); and *CEL-1*-(13-221) (pAD5-CEL-1(13-221)). Leu<sup>+</sup> His<sup>+</sup> transformants were grown in the presence of 5-FOA, and the plates were incubated for 3 days at 30 °C.



**FIG. 6. RTPase activities of CEL-1(13-221) mutants.** *A*, purification of recombinant polyhistidine-tagged CEL-1(13-221) protein. The peak fractions of the heparin-Sepharose CL-6B column were analyzed by SDS-PAGE and visualized by Coomassie Brilliant Blue staining (*top panel*) or immunoblotting with monoclonal anti-polyhistidine antibody (*bottom panel*). 400 and 50 ng of protein were loaded for the *top* and *bottom* panels, respectively. *Lane 1*, wild-type CEL-1(13-221); *lane 2*, C136S; *lane 3*, R142K; *lane 4*, D76N; *lane 5*, E111Q; *lane 6*, D112N. For reasons that are not clear, the D76N mutant shows slightly altered mobility. *B*, RTPase assay. The wild-type and mutated CEL-1(13-221) proteins were incubated at 30 °C for 10 min with 1  $\mu$ M termini of a [ $\gamma$ - $^{32}$ P]GTP-labeled 65 nucleotide RNA. Reaction mixtures were analyzed by thin layer chromatography (TLC) on polyethyleneimine-cellulose plates. Released phosphate was detected by autoradiography, and radioactive spots were cut out and quantitated by liquid scintillation counting. Relative amounts of released phosphate were plotted *versus* protein amount. *C*, *in vivo* analysis of CEL-1(13-221) mutants by plasmid shuffling. YSB719 carrying pDB20H-MCE-(211-597) was transformed with the vector pAD5 or derivatives expressing the indicated CEL-1 alleles. Leu<sup>+</sup> His<sup>+</sup> transformants were tested for growth in the presence of 5-FOA. Plates were incubated for 4 days at 30 °C. *D*, immunoblot analysis of *S. cerevisiae* whole-cell extracts. YSB719 cells carrying pDB20H-MCE-(211-597) and CEL-1(13-221) derivatives were grown in selective media but without shuffling out the *CEG1/CET1* plasmid. Extracts were prepared, and 10- $\mu$ g protein was analyzed by SDS-PAGE and immunoblotting with the anti-HA antibody 12CA5. *Lane 1*, pAD5; *lane 2*, pAD5-CEL-1(13-221); *lane 3*, pAD5-CEL-1(13-221)C136S; *lane 4*, pAD5-CEL-1(13-221)C136A; *lane 5*, pAD5-CEL-1(13-221)R142K; *lane 6*, pAD5-CEL-1(13-221)R142A; *lane 7*, pAD5-CEL-1(13-221)D76N; *lane 8*, pAD5-CEL-1(13-221)E111Q; *lane 9*, pAD5-CEL-1(13-221)D112N.

of the chimeric RTPases support viability of the same strain if MCE-(211-597) replaces Ceg1 as the GTase (Fig. 5, *right*), showing that these proteins are functional. These data support our earlier conclusion that residues 235-265 of Cet1 are primarily required for proper function of Ceg1.

**Mutation Analysis of CEL-1 RTPase Domain**—Members of the PTP superfamily, including the metazoan capping enzyme RTPases, have an active site consensus sequence of (I/V)H-CXXGXXR(S/T)G. The nucleophilic cysteine attacks the phosphate. The arginine residue contributes to transition-state stabilization via the formation of hydrogen bonds with two

oxygens of the phosphate (47). Outside the active site motif, a conserved aspartic acid residue serves to stabilize the leaving group (48-50). In the PTPs, this acidic residue is believed to act as a general acid, donating a proton to the leaving group oxygen of the substrate tyrosine residue.

To examine the degree of mechanistic conservation between the PTPs and RTPases, we analyzed CEL-1 derivatives mutated at conserved residues important for the PTP mechanism. Arginine 142 in the consensus motif was mutated. Also, aspartate 76, glutamate 111, and aspartate 112 were mutated because they were candidates for the proton-donating acidic res-

idue. Arg-142 and Asp-76 are conserved in all of the PTP-like RTPases, whereas Glu-111 and Asp-112 are not (Fig. 2B). The histidine-tagged mutants C136S, R142K, D76N, E111Q, and D112N were purified from *E. coli* (Fig. 6A). Their RTPase activities were tested with [ $\gamma$ - $^{32}$ P]GTP-terminated RNA (Fig. 6B). C136S and R142K, mutated in key active site residues, were inactive. The activities of E111Q, D112N, and D76N were about 20, 50, and 10%, respectively, that of the wild-type protein.


We also tested if these mutants can support viability of a *ceg1Δcet1Δ* strain that was also expressing MCE-(211–597) (Fig. 6C). CEL-1 mutants C136S, C136A, R142K, or R142A could not support viability, whereas E111Q or D112N grew as well as the wild-type strain. The *in vivo* phenotypes correlated well with *in vitro* results. D76N, which had only 10% of wild-type activity *in vitro*, did not support viability. Immunoblotting of whole-cell extracts confirmed that all the mutants were expressed, although some variability in levels was observed (Fig. 6D). The differences in ability to support cell growth did not correlate with protein expression, since the non-functional C136S, R142K, and R142A mutants were expressed at greater levels than the functional E111Q and D112N proteins.

Residues Glu-111 and Asp-112 are not highly conserved and do not seem to be vital *in vivo* (Fig. 6C). In contrast, Asp-76 is conserved, and a D76N mutant cannot support viability in yeast. However, the D76N mutant still has partial activity *in vitro*, indicating that the carboxylate side chain is not absolutely required. We speculate that the reduced activity of D76N is not sufficient to rescue cells in the heterologous yeast system. Mutation of the equivalent residue in MCE or BVP (Asp-66 of MCE and Asp-60 of BVP) only slightly diminished the activity (51–53). Therefore, in contrast to the PTPs, general acid catalysis may not be essential for the mechanism of the RNA phosphatases.

**Effect of Chain Length of RNA on RTPase Domain of Metazoan Capping Enzyme**—The DNA primase of bacteriophage T7 uses a DNA template to make short RNA primers (2–10 nucleotides) that begin with the sequence pppApC (21). Using this system, substrates of various sizes were prepared for RTPase assays. We previously reported that CEL-1-(13–248) efficiently uses a trinucleotide substrate (pppApCpC) but not a mononucleotide (pppA) (8). Here, we prepared dimer (pppApC), trimer (pppApCpC), tetramer (pppApCpCpC), and pentamer (pppApCpCpCpC) RNAs (Fig. 7A). First, the activity of CEL-1-(13–221) was tested with dinucleotide labeled at either the  $\gamma$  (pppApC; *bold* denotes the position of the radioactive phosphate) or  $\alpha$  (pppApC) positions (Fig. 7B). CEL-1-(13–221) releases the terminal phosphate to leave a diphosphate end. This activity was not seen with CEL-1-(13–221)C136S, mutated at the active site cysteine. CEL-1-(13–221) did not have detectable nucleotide phosphohydrolase activity under these conditions (Fig. 7C).

The pH optimum of the RTPase reaction was about pH 8.0, and the reaction was severely inhibited below pH 7.0 (data not shown). Sodium vanadate is an inhibitor of PTPs that acts as a transition-state mimic (54). Vanadate also inhibited CEL-1-(13–221), with 60% inhibition observed at 1  $\mu$ M (data not shown). Like PTPs, CEL-1 RTPase is independent of, and in fact inhibited by, divalent cations (data not shown). Similar inhibition was reported for MCE, PIR1, and BVP (51, 55).

Next we tested the effect of RNA chain length (Fig. 8). CEL-1-(13–221) hydrolyzes the  $\beta$ - $\gamma$  phosphodiester bond of trinucleotide more efficiently than that of dinucleotide. Little difference was seen between tri-, tetra-, and pentanucleotides. With a double-reciprocal plot, the  $k_{cat}/K_m$  values with ATP, dinucleotide, trinucleotide, and tetranucleotide were calculated to be




**FIG. 7. Substrate specificity and catalytic properties of the CEL-1 RTPase domain.** A, substrates for the RTPase assay. [ $\gamma$ - $^{32}$ P]ATP-terminated oligoribonucleotides (pppA(pC)<sub>n</sub>pC,  $n = 0-3$ ) were synthesized with T7 DNA primase and purified with DEAE-Sephadex A-25 column chromatography. Each RNA was resolved by electrophoresis on a 36% polyacrylamide gel containing 3 M urea, and  $^{32}$ P label (asterisk) was detected by PhosphorImager. Lanes 2–5, 80 pmol of termini of dimeric (pppApC), trimeric (pppApCpC), tetrameric (pppApCpCpC), and pentameric (pppApCpCpCpC) RNAs, respectively. In lane 1, [ $\gamma$ - $^{32}$ P]ATP was loaded as a marker. B, RTPase activity. Left panel, CEL-1-(13–221) releases the  $\gamma$ -phosphate. The indicated amounts of the wild-type protein (CEL-1-(13–221), lanes 3–5) and the active site cysteine mutant (CEL-1-(13–221)C136S, lanes 6–8) were incubated for 10 min at 30 °C with 0.1  $\mu$ M (termini) [ $\gamma$ - $^{32}$ P]ATP-terminated dinucleotide RNA (pppApC). The reaction mixtures were analyzed by TLC on polyethyleneimine-cellulose plates, and  $^{32}$ P label (asterisk) was detected by PhosphorImager. In lane 1 of each panel, the substrate was incubated with 1 unit of calf intestinal phosphatase (CIP) to determine the position of free phosphate. Right panel, CEL-1-(13–221) leaves a 5' diphosphate end. Reactions in lanes 1–8 were identical to those in lanes 1–8 of the left panel, except [ $\gamma$ - $^{32}$ P]ATP-terminated dinucleotide RNAs were replaced with [ $\alpha$ - $^{32}$ P]ATP-terminated dinucleotide RNA (pppApC). The position of pppApC was determined using ADP-terminated dimer as standards (8). C, nucleotide phosphohydrolase activity. Reactions in lanes 1–5 were identical to those in lanes 1–5 in the left panel of B, except [ $\gamma$ - $^{32}$ P]ATP-terminated dinucleotide RNAs were replaced with 5  $\mu$ M [ $\gamma$ - $^{32}$ P]ATP (pppA). Incubation was for 30 min at 30 °C.

$5.5 \times 10^4$ ,  $0.5 \times 10^5$ ,  $4.6 \times 10^5$ ,  $5.1 \times 10^5$   $\text{M}^{-1} \text{s}^{-1}$ , respectively. The same length dependence was observed with full-length MCE and MCE-(1–210) (data not shown), indicating that two phosphodiester bonds are necessary for optimal fit of the RNA



FIG. 8. **Effect of RNA chain length on the CEL-1 RTPase.** The indicated amounts of CEL-1(13–221) were incubated for 10 min at 30 °C with 1  $\mu$ M termini of [ $\alpha$ - $^{32}$ P]ATP-terminated di-, tri-, tetra-, and pentanucleotides. The reaction mixtures were analyzed by TLC on polyethyleneimine-cellulose plates.  $^{32}$ P label was detected by autoradiography, and radioactive spots on polyethyleneimine-cellulose plate were cut out and counted by liquid scintillation.



substrate into the active site of metazoan capping enzyme RTPases.

**CEL-1 Is Essential for Embryonic Development and CTD Ser-2 Phosphorylation**—To investigate the requirement for *CEL-1* *in vivo*, we used RNAi to inhibit its expression during embryogenesis (56). The early embryo provides an advantageous system for analyzing functions of essential transcription or mRNA processing machinery components *in vivo*. The initial stages of *C. elegans* development are orchestrated by maternally derived proteins and mRNAs, making it possible for embryos to survive until approximately the 100-cell stage when new mRNA transcription is prevented (27, 57).

*cel-1(RNAi)* embryos arrested development after forming ~100 cells that lacked any signs of differentiation (Fig. 9A). This terminal arrest phenotype is very similar to that observed when the pol II large subunit or various other broadly essential mRNA transcription factors are inhibited by RNAi (23, 24, 27, 57). However, early cell division timing and cleavage planes were normal in *cel-1(RNAi)* embryos, suggesting that these embryos contained appropriate maternal mRNA stores (not shown). One abnormality was the cell cycle period of the endodermal precursor cells Ea and Ep, which was shortened compared with wild type. This particular cell cycle abnormality characteristically occurs in response to broad defects in early embryonic transcription, including mutation or RNAi knock-down of the *C. elegans* orthologs of the transcription elongation factor genes *spt5* and *spt6* (23, 24, 27, 57). Together, the data suggest that lack of *cel-1* activity may significantly impair new embryonic mRNA production.

To further characterize how the process of mRNA production was affected in *cel-1(RNAi)* embryos, phosphorylation of RNA polymerase II was analyzed. The CTD of the pol II large subunit consists of repeats based in the consensus sequence YSPTSPS (42 copies in *C. elegans*). The CTD interacts with mRNA processing factors, linking them to the transcribing polymerase (58, 59). Near promoters, the CTD repeat is primarily phosphorylated on serine 5 by the transcription factor IIH kinase, recruiting mRNA capping enzyme (26, 60, 61). As pol II moves away from the promoter, the CTD phosphorylation

shifts primarily to serine 2 (60). During metazoan transcription, CTD serine 2 is phosphorylated primarily by the kinase P-TEFb (CDK-9/cyclin T) (23, 62). CTD Ser-5 and Ser-2 phosphorylation can be specifically detected in embryonic nuclei by staining with the P-CTD and H5 antibodies, respectively (26, 27, 63), which we refer to as  $\alpha$ -Ser(P)-5 and  $\alpha$ -Ser(P)-2 for clarity (Fig. 9, C and D).


In the early *C. elegans* embryo, the appearance of both  $\alpha$ -Ser(P)-5 and  $\alpha$ -Ser(P)-2 staining depends upon transcription. Staining with  $\alpha$ -Ser(P)-5 and  $\alpha$ -Ser(P)-2 is not detected in embryonic nuclei until the three-to-four cell stage, when new mRNA transcription begins (63). At later stages, the patterns and intensity of this staining closely parallel transcription activity in embryonic cells. For example, both types of staining are eliminated or reduced in tandem by RNAi depletion of transcription initiation factors such as TFIIB (*ttb-1*) (24, 27). In contrast, when the elongation factor CDK-9 is depleted by RNAi, Ser-5 phosphorylation levels appear normal, but Ser-2 phosphorylation is undetectable (23).

In *cel-1(RNAi)* embryos, total levels of the pol II large subunit AMA-1 are unaffected (Fig. 9B), but CTD phosphorylation was highly abnormal. As in wild type embryos, in *cel-1(RNAi)* embryos Ser-5 phosphorylation was detectable as bright punctate staining pattern in somatic nuclei (Fig. 9C). In contrast, in *cel-1(RNAi)* embryos levels of specific  $\alpha$ -Ser(P)-2 staining were dramatically reduced, to a level only slightly higher than the background observed in *ama-1(RNAi)* embryos (Fig. 9D). Levels of the CTD Ser-2 kinase CDK-9 appeared to be normal in *cel-1(RNAi)* embryonic nuclei, arguing that the drop in CTD phosphorylation was not an indirect effect (Fig. 9B). The specific and substantial defect in CTD Ser-2 phosphorylation suggests that when CEL-1 levels are depleted, the normal progression of CTD phosphorylation during transcription is disrupted at most or possibly all genes.

## DISCUSSION

Here we characterize the full-length *C. elegans* capping enzyme, CEL-1. Based on cDNAs in the EST databases, CEL-1 is a 623-amino acid protein with both RTPase and GTase activi-





**FIG. 9. Cel-1 is required for embryonic development and CTD serine 2 phosphorylation.** A, terminal developmental arrest of *cel-1(RNAi)* embryos. Wild-type (WT) and RNAi embryos were examined by differential interference (DIC) microscopy. The wild-type embryo in the left panel is about to hatch, but *ama-1(RNAi)* (pol II) and *cel-1(RNAi)* embryos each arrested with ~100 cells. Embryos measure ~50  $\mu$ m. B, expression of RNA pol II and the CDK-9 kinase in wild-type and *cel-1(RNAi)* embryos. Embryos were stained simultaneously with 4',6'-diamidino-2-phenylindole hydrochloride (DAPI) to visualize DNA, a CDK-9 antibody (8WG16), and an antibody to the unphosphorylated pol II large subunit (8WG16). C, CTD serine 5 phosphorylation in *cel-1(RNAi)* embryos. Wild-type or RNAi embryos (presented in rows) were stained with 4',6'-diamidino-2-phenylindole hydrochloride, an serine/arginine-rich protein antibody (16M3) as a control, or an antibody to CTD phosphoserine 5 (26), as indicated. An expanded  $\alpha$ -Ser(P)-5 stained somatic nucleus (white arrow) is shown in the right column. Representative embryos at comparable stages are presented. D, *cel-1* is required for CTD serine 2 phosphorylation. Wild type or RNAi embryos were stained with 4',6'-diamidino-2-phenylindole hydrochloride, a C/EBP-binding protein (CBP)-1 antibody for a staining control (82), and an antibody to CTD phosphoserine 2 (H5) (83, 84). An expanded  $\alpha$ -Ser(P)-2-stained somatic nucleus is shown as in C. In the transcriptionally silent germline precursor (red arrow), only weak cross-reactivity with perinuclear germline P granules is detected. Mitotic nuclei, which also cross-react with  $\alpha$ -Ser(P)-2 in the absence of the pol II epitope (23, 63), are marked with asterisks. Representative embryos of comparable stages are shown.

ties. This matches the size of the enzyme-GMP intermediate detected in *C. elegans* nuclear extract (Fig. 1). Interestingly, multiple cDNAs for human and *Xenopus* capping enzymes have been described, possibly produced by alternative splicing of mRNA (31–33). These cDNA variants encode an intact N-terminal RTPase domain but have either internal deletions or truncations in the C-terminal GTase domain. As a result, the proteins from these variants would only have RTPase activity. PCR analyses showed that these short forms are expressed, but their physiological function is unknown. To date, no cDNAs corresponding to a shortened capping enzyme have been found in the *C. elegans* EST data base. CEL-1 was originally pre-

dicted to have 573 amino acids. CEL-1(1–585) has RTPase activity but does not complement a *S. cerevisiae* GTase mutant *ceg1Δ* (Fig. 3). Therefore, CEL-1 residues 586–623 are not required for protein stability or proper localization but are essential for GTase activity.

The CEL-1 RTPase domain (3) was the founding member of a subfamily of PTP-like RNA phosphatases. This subfamily includes the capping enzyme RTPases and RNA tri- and diphosphatases, whose functions are unknown (Fig. 2B). All members contain a nucleophilic cysteine necessary for activity (3, 8, 41, 51, 55, 64, 65). A phosphocysteine intermediate was detected with MCE and BVP (52, 53). Other PTP-like enzymes with substrates other than phosphotyrosine have been reported; these include the phosphoinositide phosphatase PTEN/MMAC1 and myotubularin (66) and *S. cerevisiae* arsenite reductase Acr2 (67).

In PTPs, the formation and hydrolysis of the phosphocysteine intermediate of PTP requires transition-state stabilization by the arginine residue within the consensus motif (4–7). Mutagenesis of MCE (51, 52), BVP (53), and CEL-1 (Fig. 6) shows that this residue is essential for RNA phosphatase activity, providing further evidence that the PTP and RNA phosphatases use the same enzymatic mechanism. On the other hand, mutation of a conserved aspartic acid residue in the RTPases (Asp-76 of CEL-1, Asp-66 of MCE, and Asp-60 of BVP; see Fig. 2B) only slightly diminishes activity (Fig. 6; Refs. 51–52). The equivalent mutations in PTPs lower activity by  $10^2$ – $10^5$ -fold (4–7). X-ray crystallography of MCE-(1–210) shows that Asp-66 is positioned differently from the essential general acid aspartate loop described for PTPs (52). Apparently, the RTPase mechanism does not conserve the function of this residue.

Both CEL-1(13–221) and MCE-(1–210) can remove the  $\gamma$ -phosphate from the 5' end of a dinucleotide (Fig. 7 and data not shown). However, maximal activity is observed on substrates that are three nucleotides or longer (Fig. 8 and data not shown). The *S. cerevisiae* RTPase Cet1 is unrelated to PTPs, and its reaction mechanism is different from that of metazoan RTPases (40). However, Cet1 also acts on dinucleotide and trinucleotide RNAs efficiently (18).<sup>3</sup> Diphosphate-ended oligonucleotides such as ppApG, ppGpC, and ppGpCpC are active as guanylyl acceptors for mammalian and yeast GTases (68–72). Structural studies on RNA polymerase II suggest that RNA exits polymerase in the vicinity of the CTD (73), where capping enzymes will be bound. Capping occurs around the time mRNAs are about 30 nucleotides in length (74, 75). Therefore, capping enzyme probably recognizes the first few phosphodiester bonds of nascent RNA that emerge from the body of pol II and immediately caps the mRNA.

RTPases and GTases are typically linked with each other, either on the same protein (metazoans) or in a complex (yeast). In *S. cerevisiae*, the interaction between the GTase (Ceg1) and RTPase (Cet1) subunits is essential for cell viability. Cet1 cannot be replaced by the RTPase domains from MCE or CEL-1, presumably because these RTPases cannot interact with Ceg1. It was originally proposed that the primary role of the linkage between GTase and RTPase on a single polypeptide was to guide RTPase to pol II transcription complex (43, 64). However, both CEL-1(13–221) and MCE-(1–210) can support viability when Ceg1 is replaced with MCE-(211–597), *S. pombe* pce1, or *C. albicans* Cgt1 (Fig. 4, A and B). Because we did not detect any tight interaction between these RTPases and GTases (Fig. 4C), we conclude that the metazoan RTPase domain can be targeted to pre-mRNA and function without any linkage to GTase. The primary function of the Cet1 interaction with Ceg1 is instead required for the activity of Ceg1 (10, 11). Other

fungus and metazoan GTases do not require an interaction with RTPase for activity (45, 46).

Although we found that the link between RTPase and GTase domains is not absolutely required for the capping enzymes of metazoans or fungi other than *S. cerevisiae*, this does not mean that the interaction is unimportant. To substitute for Cet1 *in vivo*, it was necessary to overexpress the isolated metazoan RTPase domain with a strong promoter and a high copy plasmid (Ref. 76 and this study). In contrast, a low copy plasmid of the full-length enzyme was sufficient for rescuing a *cel1Δ* strain (52). Transfection experiments showed that MCE-(1–210) is mostly cytoplasmic in mammalian cells (51). This may also be true in *S. cerevisiae*. Overexpression may be necessary to drive sufficient amounts of RTPase into the nucleus and into proximity with the mRNA 5' end. Alternatively, RTPases may independently bind pol II or a pol II-associated protein. HIV-1 Tat protein binds to both full-length MCE as well as the isolated GTase and RTPase domains (77). There could be a corresponding cellular protein(s) that mediates the association of RTPase domain with the pol II complex or RNA chain. Whatever mechanism is used, isolated RTPase domains function more efficiently *in vivo* when it is linked to a GTase domain.

Finally, we examined the requirement for CEL-1 *in vivo* using RNA-mediated inactivation of the gene. *cel-1(RNAi)* embryos arrest development with a phenotype that is characteristic of a broad transcription defect. A similar phenotype is seen upon RNAi knockdown of *ama-1* (pol II), *ttb-1* (TFIIB), or multiple TAFs (23, 24, 27). One *cel-1(RNAi)* phenotype is strikingly different from effects seen upon depletion of basal initiation factors. In those cases, levels of CTD phosphorylation at both serine 5 and serine 2 were lowered in parallel, often reduced to undetectable levels. For example, in *ttb-1(RNAi)* embryos, in which basal factor TFIIB is knocked down, both serine 5 and serine 2 phosphorylation are reduced to background (23, 27). In *cel-1(RNAi)* embryos, CTD serine 5 phosphorylation appears to be relatively unaffected, whereas serine 2 phosphorylation is dramatically reduced (Fig. 9B). The only other example of this "uncoupling" of CTD serine 5 and 2 phosphorylation occurred when we depleted either of the P-TEFb components, CDK-9, or cyclin T (23). Levels of the CDK-9 kinase appear normal in *cel-1(RNAi)* embryos, however. Because serine 5 phosphorylation occurs primarily near the promoter, the generally normal levels in *cel-1(RNAi)* embryos suggest that transcription initiation may be close to normal. The markedly decreased levels of serine 2 phosphorylation, a modification linked to elongation phase, suggests that the absence of capping enzyme interrupts the progression of transcription. It will be interesting to determine whether the lack of capping enzyme decreases the efficiency with which P-TEFb or other elongation factors are recruited to transcribed genes. This would be the latest of many connections have recently emerged between transcription elongation and mRNA processing.

**Acknowledgments**—We thank Drs. Aaron J. Shatkin and Fabio Piano for communicating results before publication, Gary Ruvkun for supplying *C. elegans* nuclear extract, Dale Wigley for pET-A103R, Gerhard Wagner and Kylie Walter for pT7-911Q, Takahiro Kusakabe for designing the sequences of synthetic oligonucleotides for preparation of short RNA with T7 DNA primase, and Robin Buratowski for help with the plasmid and oligo tables.

## REFERENCES

- Furuichi, Y., and Shatkin, A. J. (2000) *Adv. Virus Res.* **55**, 135–184
- Shuman, S. (2000) *Prog. Nucleic Acid Res. Mol. Biol.* **66**, 1–40
- Takagi, T., Moore, C. R., Diehn, F., and Buratowski, S. (1997) *Cell* **89**, 867–873
- Denu, J. M., Stuckey, J. A., Saper, M. A., and Dixon, J. E. (1996) *Cell* **87**, 361–364
- Fauman, E. B., and Saper, M. A. (1996) *Trends Biochem. Sci.* **21**, 413–417
- Barford, D., Das, A. K., and Egloff, M.-P. (1998) *Annu. Rev. Biophys. Biomol. Struct.* **27**, 133–164
- Denu, J. M., and Dixon, J. E. (1998) *Curr. Opin. Chem. Biol.* **2**, 633–641
- Takagi, T., Taylor, G. S., Kusakabe, T., Charbonneau, H., and Buratowski, S. (1998) *Proc. Natl. Acad. Sci. U. S. A.* **95**, 9808–9812
- Fresco, L. D., and Buratowski, S. (1994) *Proc. Natl. Acad. Sci. U. S. A.* **91**, 6624–6628
- Cho, E.-J., Rodriguez, C. R., Takagi, T., and Buratowski, S. (1998) *Genes Dev.* **12**, 3482–3487
- Takase, Y., Takagi, T., Komarnitsky, P. B., and Buratowski, S. (2000) *Mol. Cell. Biol.* **24**, 9307–9316
- Gietz, D., St. Jean, A., Woods, R. A., and Schiestl, R. (1992) *Nucleic Acids Res.* **20**, 1425
- Ausubel, F. M., Brent, R., Kingston, R. E., Moore, D. D., Seidman, J. G., Smit, J. A., and Struhl, K. (eds) (1991) *Current Protocols in Molecular Biology*, John Wiley & Sons, Inc., New York
- Guthrie, C., and Fink, G. (1991) *Methods Enzymol.* **194**, 1–933
- Kunkel, T. A., Roberts, J. D., and Zakour, R. A. (1987) *Methods Enzymol.* **154**, 367–382
- Vieira, J., and Messing, J. (1987) *Methods Enzymol.* **153**, 3–11
- Ho, S. N., Hunt, H. D., Horton, R. M., Pullen, J. K., and Pease, L. R. (1989) *Gene (Amst.)* **77**, 51–59
- Rodriguez, C. R., Takagi, T., Cho, E.-J., and Buratowski, S. (1999) *Nucleic Acids Res.* **27**, 2181–2188
- Studier, F. W., Rosenberg, A. H., Dunn, J. J., and Dubendorff, J. W. (1990) *Methods Enzymol.* **185**, 60–89
- Matsuo, H., Moriguchi, T., Takagi, T., Kusakabe, T., Buratowski, S., Sekine, M., Kyogoku, Y., and Wagner, G. (2000) *J. Am. Chem. Soc.* **122**, 2417–2421
- Kusakabe, T., and Richardson, C. C. (1997) *J. Biol. Chem.* **272**, 5943–5951
- Ichetovkin, I. E., Abramochkin, G., and Shrader, T. E. (1997) *J. Biol. Chem.* **272**, 33009–33014
- Shim, E. Y., Walker, A. K., Shi, Y., and Blackwell, T. K. (2002) *Genes Dev.* **16**, 2135–2146
- Shim, E. Y., Walker, A. K., and Blackwell, T. K. (2002) *J. Biol. Chem.* **277**, 30413–30416
- Bellier, S., Dubois, M. F., Nishida, E., and Almouzni, G., and Bensaude, O. (1997) *EMBO J.* **16**, 6250–6252
- Schroeder, S. C., Schwer, B., Shuman, S., and Bentley, D. (2000) *Genes Dev.* **14**, 2435–2440
- Walker, A. K., Rothman, J. H., Shi, Y., and Blackwell, T. K. (2001) *EMBO J.* **20**, 5269–5279
- Wang, S. P., Deng, L., Ho, C. K., and Shuman, S. (1997) *Proc. Natl. Acad. Sci. U. S. A.* **94**, 9573–9578
- Yue, Z., Maldonado, E., Pillutla, R., Cho, H., Reinberg, D., and Shatkin, A. J. (1997) *Proc. Natl. Acad. Sci. U. S. A.* **94**, 12898–12903
- McCracken, S., Fong, N., Rosonina, E., Yankulov, K., Brothers, G., Siderovski, D., Hessel, A., Foster, S., Amgen EST Project, Shuman, S., and Bentley, D. L. (1997) *Genes Dev.* **11**, 3306–3318
- Tsukamoto, T., Shibagaki, Y., Murakoshi, T., Suzuki, M., Nakamura, A., Gotoh, H., and Mizumoto, K. (1998) *Biochem. Biophys. Res. Commun.* **243**, 101–108
- Yamada-Okabe, T., Doi, R., Shimmi, O., Arisawa, M., and Yamada-Okabe, H. (1998) *Nucleic Acids Res.* **26**, 1700–1706
- Yokoska, J., Tsukamoto, T., Miura, K., Shiokawa, K., and Mizumoto, K. (2000) *Biochem. Biophys. Res. Commun.* **268**, 617–624
- Hakansson, K., Doherty, A. J., Shuman, S., and Wigley, D. B. (1997) *Cell* **89**, 545–554
- Hakansson, K., and Wigley, D. B. (1998) *Proc. Natl. Acad. Sci. U. S. A.* **95**, 1505–1510
- Shuman, S., and Schwer, B. (1995) *Mol. Microbiol.* **17**, 405–410
- Itoh, N., Yamada, H., Kaziro, Y., and Mizumoto, K. (1987) *J. Biol. Chem.* **262**, 1989–1995
- Shibagaki, Y., Itoh, N., Yamada, H., Nagata, S., and Mizumoto, K. (1992) *J. Biol. Chem.* **267**, 9521–9528
- Tsukamoto, T., Shibagaki, Y., Imajoh-Ohmi, S., Murakoshi, T., Suzuki, M., Nakamura, A., Gotoh, H., and Mizumoto, K. (1997) *Biochem. Biophys. Res. Commun.* **239**, 116–122
- Lima, C. D., Wang, L. K., and Shuman, S. (1999) *Cell* **99**, 533–543
- Ho, C. K., Sriskanda, V., McCracken, S., Bentley, D., Schwer, B., and Shuman, S. (1998) *J. Biol. Chem.* **273**, 9577–9585
- Field, J., Nikawa, J.-I., Broek, D., MacDonald, B., Rodgers, L., Wilson, I. A., Lerner, R. A., and Wigler, M. (1988) *Mol. Cell. Biol.* **8**, 2159–2165
- Cho, E.-J., Takagi, T., Moore, C. R., and Buratowski, S. (1997) *Genes Dev.* **11**, 3319–3326
- Ho, C. K., and Shuman, S. (1999) *Mol. Cell* **3**, 405–411
- Pei, Y., Hausmann, S., Ho, C. K., Schwer, B., and Shuman, S. (2001) *J. Biol. Chem.* **276**, 28075–28082
- Takagi, T., Cho, E.-J., Janoo, R. T. K., Polodny, V., Takase, Y., Keogh, M.-C., Woo, S.-A., Fresco-Cohen, L. D., Hoffman, C. S., and Buratowski, S. (2002) *Eukaryot. Cell* **1**, 448–457
- Zhang, Z.-Y., Wang, Y., Wu, L., Fauman, E. B., Stuckey, J. A., Schubert, H. L., Saper, M. A., and Dixon, J. E. (1994) *Biochemistry* **33**, 15266–15270
- Zhang, Z.-Y., Wang, Y., and Dixon, J. E. (1994) *Proc. Natl. Acad. Sci. U. S. A.* **91**, 1624–1627
- Hengge, A. C., Sowa, G. A., Wu, L., and Zhang, Z.-Y. (1995) *Biochemistry* **34**, 13982–13987
- Denu, J. M., Zhou, G., Guo, Y., and Dixon, J. E. (1995) *Biochemistry* **34**, 3396–3403
- Wen, Y., Yue, Z., and Shatkin, A. J. (1998) *Proc. Natl. Acad. Sci. U. S. A.* **95**, 12226–12231
- Changela, A., Ho, C. K., Martins, A., Shuman, S., and Mondragon, A. (2001) *EMBO J.* **20**, 2575–2586
- Martins, A., and Shuman, S. (2000) *J. Biol. Chem.* **275**, 35070–35076
- Denu, J. M., Lohse, D. L., Vijayalakshmi, J., Saper, M. A., and Dixon, J. E. (1996) *Proc. Natl. Acad. Sci. U. S. A.* **93**, 2493–2498
- Deshpande, T., Takagi, T., Hao, L., Buratowski, S., and Charbonneau, H.



- (1999) *J. Biol. Chem.* **274**, 16590–16594
56. Fire, A., Xu, S., Montgomery, M. K., Kostas, S. A., Driver, S. E., and Mello, C. C. (1998) *Nature* **391**, 806–811
57. Powell-Coffman, J. A., Knight, J., and Wood, W. B. (1996) *Dev. Biol.* **178**, 472–483
58. Hirose, Y., and Manley, J. L. (2000) *Genes Dev.* **14**, 1415–1429
59. Fong, N., and Bentley, D. L. (2001) *Genes Dev.* **15**, 1783–1795
60. Komarnitsky, P., Cho, E.-J., and Buratowski, S. (2000) *Genes Dev.* **14**, 2452–2460
61. Cho, E.-J., Kobor, M. S., Kim, M., Greenblatt, J., and Buratowski, S. (2001) *Genes Dev.* **15**, 3319–3329
62. Price, D. H. (2000) *Mol. Cell. Biol.* **20**, 2629–2634
63. Seydoux, G., and Dunn, M. A. (1997) *Development* **124**, 2191–2201
64. Ho, C. K., Schwer, B., and Shuman, S. (1998) *Mol. Cell. Biol.* **18**, 5189–5198
65. Gross, C. H., and Shuman, S. (1998) *J. Virol.* **72**, 7057–7063
66. Maehama, T., Taylor, G. S., and Dixon, J. E. (2001) *Annu. Rev. Biochem.* **70**, 247–279
67. Mukhopadhyay, R., and Rosen, B. P. (2001) *J. Biol. Chem.* **276**, 34738–34742
68. Vankatesan, S., and Moss, B. (1980) *J. Biol. Chem.* **255**, 2835–2842
69. Wang, D., Furuichi, Y., and Shatkin, A. J. (1982) *Mol. Cell. Biol.* **2**, 993–1001
70. Wang, D., and Shatkin, A. J. (1984) *Nucleic Acids Res.* **23**, 2303–2315
71. Mizumoto, K., Kaziro, Y., and Lipman, F. (1982) *Proc. Natl. Acad. Sci. U. S. A.* **79**, 1693–1697
72. Itoh, N., Mizumoto, K., and Kaziro, Y. (1984) *J. Biol. Chem.* **259**, 13930–13936
73. Cramer, P., Bushnell, D. A., and Kornberg, R. D. (2001) *Science* **292**, 1863–1876
74. Jove, R., and Manley, J. L. (1984) *J. Biol. Chem.* **259**, 8513–8521
75. Rasmussen, E. B., and Lis, J. T. (1993) *Proc. Natl. Acad. Sci. U. S. A.* **90**, 7923–7927
76. Hausmann, S., Ho, C. K., Schwer, B., and Shuman, S. (2001) *J. Biol. Chem.* **276**, 36116–36124
77. Chiu, Y.-L., Coronel, E., Ho, C. K., Shuman, S., and Rana, T. M. (2001) *J. Biol. Chem.* **276**, 12959–12966
78. Altschul, S. F., Thoma, L. M., Alejandro, A. S., Jinghui, Z., Zheng, Z., Webb, M., and Lipman, D. J. (1997) *Nucleic Acids Res.* **25**, 3389–3402
79. Yuan, Y., Li, D.-M., and Sun, H. (1998) *J. Biol. Chem.* **273**, 20347–20353
80. Sheng, Z., and Charbonneau, H. (1993) *J. Biol. Chem.* **268**, 4728–4733
81. Sikorski, R. S., and Hieter, P. (1989) *Genetics* **122**, 19–27
82. Victor, M., Bei, Y., Gay, F., Calvo, D., Mello, C., and Shi, Y. (2002) *EMBO Rep.* **3**, 50–55
83. Bregman, D. B. X., Du, L., van der Zee, S., and Warren, S. L. (1995) *J. Cell Biol.* **129**, 287–298
84. Patturajan, M., Schulte, R. J., Sefton, B. M., Berezney, R., Vincent M., Bensaude, O., Warren, S. L., and Corden, J. L. (1998) *J. Biol. Chem.* **273**, 4689–4694